Published in AIDS Rev on May 18, 2011
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One (2012) 1.24
Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19
Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS One (2012) 1.12
HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10
Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. AIDS Res Hum Retroviruses (2014) 0.92
Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals. AIDS (2015) 0.90
Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med (2015) 0.90
Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One (2011) 0.89
Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges. AIDS Rev (2013) 0.88
An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp (2014) 0.87
Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses (2015) 0.86
Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing. J Clin Microbiol (2014) 0.84
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med (2016) 0.83
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. PLoS One (2013) 0.82
Increasing HIV-1 Drug Resistance Between 2010 and 2012 in Adults Participating in Population-Based HIV Surveillance in Rural KwaZulu-Natal, South Africa. AIDS Res Hum Retroviruses (2016) 0.81
Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structure. BMC Genomics (2014) 0.81
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. Antimicrob Agents Chemother (2015) 0.78
Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates. J Clin Microbiol (2012) 0.78
Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr (2015) 0.77
HIV-1 pol diversity among female bar and hotel workers in Northern Tanzania. PLoS One (2014) 0.77
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. PLoS One (2014) 0.77
Transmitted HIV drug resistance in treatment-naive Romanian patients. J Med Virol (2013) 0.77
Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material. AIDS Res Hum Retroviruses (2014) 0.77
Short communication: prevalence of HIV type 1 transmitted drug resistance in Slovenia: 2005-2010. AIDS Res Hum Retroviruses (2012) 0.77
Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland. J Int AIDS Soc (2014) 0.77
HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey. Med Microbiol Immunol (2015) 0.76
HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland. BMC Infect Dis (2012) 0.76
Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Antimicrob Agents Chemother (2016) 0.76
Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran. PLoS One (2015) 0.76
Ten years survey of primary HIV-1 resistance in Serbia: the occurrence of multiclass resistance. AIDS Res Hum Retroviruses (2014) 0.76
HIV drug resistance testing among patients failing second line antiretroviral therapy-Comparison of in-house and commercial sequencing. J Virol Methods (2016) 0.75
HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey. AIDS Res Hum Retroviruses (2015) 0.75
The global spread of HIV-1 subtype B epidemic. Infect Genet Evol (2016) 0.75
Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba. PLoS One (2015) 0.75
An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. PLoS One (2016) 0.75
Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland. Med Sci Monit (2017) 0.75
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One (2017) 0.75
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A (2002) 3.46
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS (2003) 3.14
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood (2003) 2.70
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res (2003) 2.37
High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS (2002) 2.36
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis (2004) 2.21
Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis (2009) 2.13
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med (2009) 2.06
HBV viremia in newborns of HBsAg(+) predominantly Caucasian HBeAg(-) mothers. J Clin Virol (2010) 2.04
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 1.98
Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.96
Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother (2012) 1.95
High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother (2010) 1.94
Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS (2002) 1.92
Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother (2007) 1.89
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr (2007) 1.88
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol (2008) 1.84
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis (2009) 1.81
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80
HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps. PLoS One (2013) 1.77
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol (2005) 1.75
Hypothyroidism as a cause of rhabdomyolysis. Endocr J (2002) 1.70
Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol (2013) 1.69
Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. Blood (2012) 1.69
Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS (2002) 1.68
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS (2006) 1.68
Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol (2009) 1.67
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS (2002) 1.67
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis (2005) 1.66
Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation (2003) 1.62
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology (2009) 1.58
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis (2011) 1.57
Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS (2005) 1.55
Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS (2002) 1.55
Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS (2005) 1.54
Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit (2004) 1.53
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. AIDS Res Hum Retroviruses (2008) 1.53
Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis (2005) 1.52
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS (2005) 1.52
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 1.52
Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS (2012) 1.52
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS (2007) 1.52
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS (2002) 1.48
CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 1.48
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother (2006) 1.46
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol (2008) 1.45
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother (2006) 1.45
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS (2004) 1.44
Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother (2009) 1.43
Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol (2004) 1.42
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol (2011) 1.42
HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr (2011) 1.42
Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS (2003) 1.42
Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother (2008) 1.42
Antiretroviral drugs and liver injury. AIDS (2008) 1.40
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Technologies for measuring HIV-1 drug resistance. HIV Clin Trials (2002) 1.39
Gender differences in the treatment of HIV infection. Pharmacol Res (2008) 1.39
Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy. AIDS (2002) 1.39
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol (2003) 1.36
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One (2013) 1.36
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis (2005) 1.33
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother (2006) 1.33
Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol (2008) 1.32
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol (2005) 1.32
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol (2009) 1.31
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods (2006) 1.31